BeOne Medicines (ONC) Common Equity (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Common Equity of $4.8 billion for Q1 2026, up 36.03% year-over-year from $3.5 billion in Q1 2025, and up 9.15% quarter-over-quarter from $4.4 billion in Q4 2025.
BeOne Medicines (ONC) Common Equity (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Common Equity for 12 consecutive years, with $4.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 36.03% year-over-year to $4.8 billion; the TTM figure through Mar 2026 stood at $4.8 billion (up 36.03% YoY), while the FY2025 annual figure was $4.4 billion, up 30.88% from the prior year.
- Common Equity rose to $4.8 billion in Q1 2026 per ONC's latest filing, from $4.4 billion in the prior quarter.
- Across five years, Common Equity topped out at $5.8 billion in Q1 2022 and bottomed at $3.3 billion in Q4 2024.
- Historically, Common Equity has averaged $4.1 billion across 5 years, with a median of $3.8 billion in 2023.
- On a YoY basis, Common Equity climbed as much as 44.22% in 2022 and fell as far as 28.52% in 2022.
- BeOne Medicines' Common Equity stood at $4.4 billion in 2022, then retreated by 19.3% to $3.5 billion in 2023, then declined by 5.8% to $3.3 billion in 2024, then jumped by 30.88% to $4.4 billion in 2025, then climbed by 9.15% to $4.8 billion in 2026.
- Business Quant data shows ONC's Common Equity at $4.8 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.17 Bn |
| Mar 31, 2026 | 4.76 Bn |
| Dec 31, 2025 | 4.36 Bn |
| Sep 30, 2025 | 4.13 Bn |
| Jun 30, 2025 | 3.77 Bn |
| Mar 31, 2025 | 3.50 Bn |
| Dec 31, 2024 | 3.33 Bn |
| Sep 30, 2024 | 3.44 Bn |
| Jun 30, 2024 | 3.37 Bn |
| Mar 31, 2024 | 3.36 Bn |
| Dec 31, 2023 | 3.54 Bn |
| Sep 30, 2023 | 3.76 Bn |
| Jun 30, 2023 | 3.80 Bn |
| Mar 31, 2023 | 4.16 Bn |
| Dec 31, 2022 | 4.38 Bn |
| Sep 30, 2022 | 4.66 Bn |
| Jun 30, 2022 | 5.20 Bn |
| Mar 31, 2022 | 5.77 Bn |
| Dec 31, 2021 | 6.13 Bn |
| Sep 30, 2021 | 3.36 Bn |